PMID- 31856440
OWN - NLM
STAT- MEDLINE
DCOM- 20191230
LR  - 20200717
IS  - 0253-2727 (Print)
IS  - 2707-9740 (Electronic)
IS  - 0253-2727 (Linking)
VI  - 40
IP  - 11
DP  - 2019 Nov 14
TI  - [Clinical prognosis analysis of patients with "double hit" multiple myeloma].
PG  - 918-923
LID - 10.3760/cma.j.issn.0253-2727.2019.11.006 [doi]
AB  - Objective: To analyze and explore the clinical characteristics and prognosis of 
      patients with "double hit" multiple myeloma (MM) . Methods: We retrospectively 
      analyzed 89 MM patients in our department of Shanghai Changzheng Hospital from 
      2010-2016. All patients were assayed by fluorescence in situ hybridization (FISH) 
      and TP53 gene sequencing, based on Dr. Walker BA proposed the "double hit" MM 
      concept, and then the clinical features and prognosis were evaluated. Results: In 
      the results, 15 (16.85%) cases harbored "double hit" showed the median PFS of 8.4 
      months and the median OS 22.2 months, which was significantly lower than 
      non-"double hit" patients with median PFS 14.2 months and the median OS 39.2 
      months, respectively (P<0.05) . Multivariate analysis displayed that the "double 
      hit" was an independent poor prognostic factor on PFS (HR=2.171, 95%CI 
      1.206-3.907, P=0.010) and OS (HR=4.106, 95%CI 2.116-7.969, P<0.001) . Moreover, 
      "double hit" MM patients had the higher adverse prognosis risk, which showed the 
      shorter median OS and PFS than stage III of R-ISS patients (PFS 8.4 vs 11.8 
      months; OS 22.2 vs 24.3 months, P<0.05, respectively) . Conclusion: Patients with 
      "double hit" MM have a very poor clinical prognosis. Prospective clinical studies 
      are urgently needed to improve these extra high risk patients.
FAU - Luo, T C
AU  - Luo TC
AD  - Department of Hematology, Changzheng Hospital, the Second Military Medical 
      University, The Myeloma and Lymphoma Center, Shanghai 200003, China.
FAU - Wu, L L
AU  - Wu LL
AD  - Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University 
      School of Medicine 200090, China.
FAU - Wu, H
AU  - Wu H
AD  - Department of Hematology, Changzheng Hospital, the Second Military Medical 
      University, The Myeloma and Lymphoma Center, Shanghai 200003, China.
FAU - Lu, M
AU  - Lu M
AD  - Shanghai Institute of Hematology, Rui Jin Hospital, Shanghai Jiao Tong University 
      School of Medicine 200090, China.
FAU - Fu, W J
AU  - Fu WJ
AD  - Department of Hematology, Changzheng Hospital, the Second Military Medical 
      University, The Myeloma and Lymphoma Center, Shanghai 200003, China.
FAU - Du, J
AU  - Du J
AD  - Department of Hematology, Changzheng Hospital, the Second Military Medical 
      University, The Myeloma and Lymphoma Center, Shanghai 200003, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
SB  - IM
MH  - China
MH  - Disease-Free Survival
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Multiple Myeloma
MH  - Prognosis
MH  - Prospective Studies
MH  - Retrospective Studies
PMC - PMC7342371
OTO - NOTNLM
OT  - Double hit
OT  - Multiple myeloma
OT  - Prognosis
EDAT- 2019/12/20 06:00
MHDA- 2019/12/31 06:00
PMCR- 2019/11/01
CRDT- 2019/12/20 06:00
PHST- 2019/12/20 06:00 [entrez]
PHST- 2019/12/20 06:00 [pubmed]
PHST- 2019/12/31 06:00 [medline]
PHST- 2019/11/01 00:00 [pmc-release]
AID - cjh-40-11-918 [pii]
AID - 10.3760/cma.j.issn.0253-2727.2019.11.006 [doi]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2019 Nov 14;40(11):918-923. doi: 
      10.3760/cma.j.issn.0253-2727.2019.11.006.